Antigens

1.	Old, Lloyd J: 39 articles (01/2008 - 02/2002)
2.	Jungbluth, Achim A: 27 articles (10/2008 - 02/2002)
3.	Rosenberg, Steven A: 24 articles (06/2008 - 01/2002)
4.	Chen, Yao-Tseng: 23 articles (06/2008 - 06/2002)
5.	Itoh, Kyogo: 22 articles (08/2008 - 03/2002)
6.	Spagnoli, Giulio C: 22 articles (01/2007 - 02/2002)
7.	Itoh, K: 20 articles (04/2004 - 02/2000)
8.	Romero, Pedro: 18 articles (09/2008 - 02/2002)
9.	Valmori, Danila: 18 articles (07/2008 - 02/2002)
10.	Ritter, Gerd: 17 articles (07/2008 - 08/2002)

Related Diseases

1.	Infection 04/01/2009 - "In this study, we evaluated the protective efficacy of immunizing mice with caseinolytic protease (ClpP) protein antigen whose gene sequences were shown to be highly conserved in different strains of Streptococcus pneumoniae in an invasive-disease model (intraperitoneal infection model), and protection against invasive challenge with 12 different serotypes of S. " 08/01/1998 - "b) Immunological study: detection of circulating antigen on the 3rd, 5th, 7th and 9th day p.i. The results showed that IL-2 was most effective when administered before and after infection in the form of significant reduction in parasitic count, least number of living tachyzoites, significant reduction in the death rate of infected mice and delayed appearance of circulating antigen with reduction in its level." 12/01/1992 - "Direct detection of respiratory syncytial (RS) virus antigen in nasopharyngeal secretions (NPS) provides the most rapid diagnostic test for RS infection, but more sensitive methods might be more beneficial in the study of virus shedding. " 12/31/2008 - "These results suggest that administration of replication-incompetent adenoviruses can induce different types of immunity depending on the expressed antigen and that recombinant adenoviruses expressing gB induced the most potent Th1-biased humoral and cellular immunity and provided effective protection against PrV infection." 07/01/2008 - "Helped memory CD8+ T cells rapidly expand in response to a secondary antigen exposure, even in the absence of T cell help and, are most efficient in protection against a re-infection. " Order ALL the reference details at left...
2.	Neoplasms (Cancer) 02/01/1987 - "In our own studies two types of approaches were also effective with the highly metastatic mouse tumor line ESb which carries a weak tumor associated antigen. " 06/01/2007 - "The Ab/SA conjugate yielding the best tumor uptake and tumor-to-normal organ ratios of radioactivity varied depending on the target antigen expression on the cell line used, with 1F5/SA and Lym-1/SA yielding the most promising results overall. " 01/01/2006 - "For this reason, DC-based immunization has been shown to be highly effective in eliciting CTL responses to viruses and tumor-associated antigens. " 06/15/2004 - "The results show that the targeting of antigen to DCs in this way is highly effective at inducing immunity and protection against the tumor, with protection being at least partially dependent on the eosinophil chemokine eotaxin." 01/01/2003 - "On the other hand, most tumors which originated from T-cell-defective mice were rejected as a sign that immunogenic tumor cells, assumed to have expressed tumor antigen, had not been eliminated in the primary tumor host. " Order ALL the reference details at left...
3.	Hepatitis B 12/01/1978 - "Eight of ten in the hepatitis B antigen-postive group cleared their antigen and had complete clinical recovery. " 07/01/2001 - "In adults at risk for a reduced response to hepatitis B vaccination [i.e., older adults (>/=40), the obese, males, and smokers], the triple antigen vaccine produced a significantly greater percentage of protected subjects (P < 0.001) and higher geometric mean titre (P < 0.001). " 07/01/2002 - "Sustained serological clearance of hepatitis B e antigen was associated with activation of CD4 positive HBV-specific T-cell reactivity and were of T-helper 1. Hence combination therapy with immunomodulatory agents and nucleoside analogues should be explored." 12/01/1993 - "Delayed clearance of hepatitis B e antigen occurred more frequently in nonresponders who had elevated pretreatment serum transaminase levels. " 12/01/1993 - "Twenty-eight (28%) nonresponders had sustained clearance of hepatitis B e antigen during follow-up. " Order ALL the reference details at left...
4.	Melanoma (Melanoma, Malignant) 02/26/1977 - "The incidence of melanoma in males and females was approximately equal, which suggests that immune responses to tumour-associated antigens may be more effective in preventing spread of tumours than in preventing their occurrence." 05/01/1988 - "The results showed that 5-azadCyd was effective in inducing antigen expression in both systems whereas HU was effective (and equally so) only in the human melanoma cell line system. " 05/01/1987 - "The chimeric antibody, but not the mouse L6 antibody, is effective against a melanoma line expressing small amounts of the L6 antigen. " 08/01/1985 - "However, a melanoma cell line that expresses minimal levels of GD3 on 13% of the cells shows insignificant lysis by MB3.6 by either of these two mechanisms, suggesting that a threshold level of antigen expression may be required for effective in vitro cytolysis. " 02/28/1979 - "The results, evaluated on the basis of absorption capacity per cell, indicate that the 2 melanoma lines had a similar amount of shared antigens, whereas the colon line was also effective in absorbing out the serum activity, but less frequently and less efficiently. " Order ALL the reference details at left...
5.	Chronic Hepatitis B 10/01/1995 - "[Long-term prognosis of chronic hepatitis B patients who cleared HBs antigen]" 11/01/2009 - "DESIGN: Our study was carried out in 215 HBs antigen positive patients, including 176 asymptomatic carriers originated from regions of variable hepatitis B virus (HBV) endemicities, and 39 hepatitis B chronic patients with delta positive serology. " 10/01/2009 - "METHODS: 127 adult e antigen-negative chronic hepatitis B patients were enrolled in this study. " 01/01/2008 - "A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients." 06/01/2005 - "The aim of the study was an evaluation of the somatic development of children with chronic hepatitis B, C and HBs antigen positive and finding the correlation between the nutrition status, the duration of disease and the aminotransferase activity. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Antibodies
2.	Antigens
3.	DNA (Deoxyribonucleic Acid)
4.	Hepatitis B e Antigens
5.	Vaccines
6.	Immunoglobulin G (IgG)
7.	Hepatitis B Surface Antigens (HBsAg)
8.	Monoclonal Antibodies
9.	Lamivudine (3TC)
10.	Immunoglobulin M (IgM)

Related Therapies and Procedures

1.	Immunotherapy
2.	Drug Therapy (Chemotherapy)
3.	Transplants (Transplant)
4.	Transplantation (Transplant Recipients)
5.	Heterologous Transplantation (Xenotransplantation)

Best Treatments:
Research Summary Report
on Infection

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 14726 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>